Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ebola virus-like particle vaccine + marburg virus-like particle vaccine
- Development stage
- Unknown
- Lead developer
- Integrated BioTherapeutics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination vaccine utilizes virus-like particles (VLPs) derived from the glycoprotein (GP) and matrix protein (VP40) of Ebola virus (EBOV) and Marburg virus (MARV). VLPs are non-infectious, as they lack the viral genome, but they mimic the authentic virus's structure and symmetry, making them highly immunogenic. They trigger both humoral (antibody) and cellular (T-cell) immune responses. This specific combination is designed to provide broad protection against multiple filoviruses, which cause severe hemorrhagic fevers. Development has primarily been led by Integrated BioTherapeutics in collaboration with USAMRIID, often utilizing a recombinant protein expression system (like baculovirus/insect cells) to produce the particles. The vaccine is typically formulated with an adjuvant to enhance the immune response.
- Other names
- Bivalent filovirus VLP vaccineEBOV+MARV VLP vaccineEbola/Marburg VLP vaccine
02
Targets
VP40 (Ebola virus matrix protein VP40)PYG (Glycogen phosphorylase)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on ebola virus-like particle vaccine + marburg virus-like particle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ebola virus-like particle vaccine + marburg virus-like particle vaccine.